Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
NCT02716116 · View on ClinicalTrials.gov ↗
Study Summary
This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment. Non-Asian, non-White participants will take TAK-788 to determine the safety and tolerability of TAK-788 treatment.
Conditions Studied
Interventions
- DRUG TAK-788
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte — Duarte
- Compassionate Cancer Care - Fountain Valley — Fountain Valley
- University of California San Diego Moores Cancer Center — La Jolla
- Pacific Shores Medical Group-Long Beach Elm — Long Beach
- Cancer and Blood Specialty Clinic — Los Alamitos
- University of California Irvine Health Chao Family Comprehensive Cancer Center — Orange
- Stanford Cancer Center - Palo Alto — Palo Alto
- SLO Oncology and Hematology Health Center — San Luis Obispo
- The Oncology Institute of Hope and Innovation — Whittier
Massachusetts
- Massachusetts General Hospital — Boston
- Beth Israel Deaconess Medical Center — Boston
- Dana Farber Cancer Institute — Boston
Arizona
- Banner MD Anderson Cancer Center — Gilbert
- The Oncology Institute of Hope and Innovation - West Tucson — Tucson
Alabama
- Brookwood Medical Center — Birmingham
Colorado
- University of Colorado Cancer Center — Aurora
Florida
- AdventHealth Orlando — Orlando
Georgia
- Winship Cancer Institute — Atlanta
Illinois
- The University of Chicago Medicine — Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2016-06-16 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02716116
The ClinicalTrials.gov registry entry for NCT02716116 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 387 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Carcinoma, Non-Small-Cell Lung appearing as the primary indexed condition, and to 1 intervention — of which TAK-788 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02716116 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, Massachusetts, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02716116 about?
NCT02716116 is a clinical study titled "A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer". This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to...
What is the current status of trial NCT02716116?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 334 participants. The study started on 2016-06-16. Estimated completion is 2026-10-31.
What conditions does trial NCT02716116 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small-Cell Lung. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02716116?
The interventions under investigation include: TAK-788 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02716116?
This trial is sponsored by Takeda, which has 387 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02716116 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.